The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) trial expanded the investigation of SGLT2 inhibitors into a population with NYHA class II–IV HF with preserved ejection fraction (>40%).30 Nearly 6,000 participants were enrolled in the trial, and less than half of them had T2D at baseline. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.